Biogen (BIIB) Stock Forecast & Price Target

Biogen's strong outlook is underpinned by significant revenue contributions from its key franchises, particularly its leading anti-amyloid therapy, Leqembi, which holds over 60% market share in a rapidly growing market, with global in-market sales reaching approximately $134 million. The company also benefits from robust commercial performance in its newer franchise, Zurzuvae, which generated approximately $65.7 million, surpassing initial expectations and demonstrating strong demand. Furthermore, Biogen's solid pipeline, including anticipated catalysts BIIB080 and BIIB122 expected in mid-2026, reinforces confidence in the long-term value and growth potential of the company.

Biogen's revenue is projected to decline by mid-single-digit percentages in FY26, translating to approximately $9.4 billion, primarily due to mounting competition and threats from generics and biosimilars within its largest revenue-generating multiple sclerosis (MS) franchise. Newer products such as Leqembi, Skyclarys, and Zurzuvae face anticipated slower sales growth and potential risks related to ongoing clinical trials, further compounding concerns about revenue generation. Additionally, management's forecast of a ~$500 million reduction in total revenue underscores the challenges ahead, particularly as the MS franchise increasingly experiences competitive pressure.